GMAB Quote, Financials, Valuation and Earnings

Evaxion Biotech AS has a net margin of 22.85% compared to Genmab AS's net margin of -64.14%. Genmab AS's return on equity of 14.86% beat Evaxion Biotech AS's return on equity of --.

Genmab AS has a consensus price target of $36.56, signalling upside risk potential of 80.03%. On the other hand Evaxion Biotech AS has an analysts' consensus of -- which suggests that it could grow by 1158.16%. Given that Evaxion Biotech AS has higher upside potential than Genmab AS, analysts believe Evaxion Biotech AS is more attractive than Genmab AS.

Genmab AS has a beta of 0.960, which suggesting that the stock is 3.991% less volatile than S&P 500. In comparison Evaxion Biotech AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion Biotech AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Evaxion Biotech AS pays out -- of its earnings as a dividend.

Genmab AS quarterly revenues are $816.4M, which are larger than Evaxion Biotech AS quarterly revenues of $3M. Genmab AS's net income of $186.6M is higher than Evaxion Biotech AS's net income of -$1.9M. Notably, Genmab AS's price-to-earnings ratio is 19.29x while Evaxion Biotech AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.58x versus 1.27x for Evaxion Biotech AS. Usually stocks with elevated PS ratios are considered overvalued.

Galecto has a net margin of 22.85% compared to Genmab AS's net margin of --. Genmab AS's return on equity of 14.86% beat Galecto's return on equity of --.

Genmab AS has a consensus price target of $36.56, signalling upside risk potential of 80.03%. On the other hand Galecto has an analysts' consensus of -- which suggests that it could grow by 111.86%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

Genmab AS has a beta of 0.960, which suggesting that the stock is 3.991% less volatile than S&P 500. In comparison Galecto has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. Galecto pays out -- of its earnings as a dividend.

Genmab AS quarterly revenues are $816.4M, which are larger than Galecto quarterly revenues of --. Genmab AS's net income of $186.6M is higher than Galecto's net income of -$3.9M. Notably, Genmab AS's price-to-earnings ratio is 19.29x while Galecto's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.58x versus -- for Galecto. Usually stocks with elevated PS ratios are considered overvalued.

IO Biotech has a net margin of 22.85% compared to Genmab AS's net margin of --. Genmab AS's return on equity of 14.86% beat IO Biotech's return on equity of --.

Genmab AS has a consensus price target of $36.56, signalling upside risk potential of 80.03%. On the other hand IO Biotech has an analysts' consensus of -- which suggests that it could grow by 1053.11%. Given that IO Biotech has higher upside potential than Genmab AS, analysts believe IO Biotech is more attractive than Genmab AS.

Genmab AS has a beta of 0.960, which suggesting that the stock is 3.991% less volatile than S&P 500. In comparison IO Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab AS pays -- of its earnings as a dividend. IO Biotech pays out -- of its earnings as a dividend.

Genmab AS quarterly revenues are $816.4M, which are larger than IO Biotech quarterly revenues of --. Genmab AS's net income of $186.6M is higher than IO Biotech's net income of -$24M. Notably, Genmab AS's price-to-earnings ratio is 19.29x while IO Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.58x versus -- for IO Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk AS has a net margin of 22.85% compared to Genmab AS's net margin of 38.28%. Genmab AS's return on equity of 14.86% beat Novo Nordisk AS's return on equity of 88.95%.

Genmab AS has a consensus price target of $36.56, signalling upside risk potential of 80.03%. On the other hand Novo Nordisk AS has an analysts' consensus of $122.11 which suggests that it could grow by 43.66%. Given that Genmab AS has higher upside potential than Novo Nordisk AS, analysts believe Genmab AS is more attractive than Novo Nordisk AS.

Genmab AS has a beta of 0.960, which suggesting that the stock is 3.991% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.400, suggesting its less volatile than the S&P 500 by 59.967%.

Genmab AS has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 1.7% to investors and pays a quarterly dividend of $0.52 per share. Genmab AS pays -- of its earnings as a dividend. Novo Nordisk AS pays out 37.96% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab AS quarterly revenues are $816.4M, which are smaller than Novo Nordisk AS quarterly revenues of $10.5B. Genmab AS's net income of $186.6M is lower than Novo Nordisk AS's net income of $4B. Notably, Genmab AS's price-to-earnings ratio is 19.29x while Novo Nordisk AS's PE ratio is 27.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab AS is 4.58x versus 9.65x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.